Does holding at 30 mg for six weeks before escalating reduce fatigue?

What I have: 30 mg · six weeks · fatigue.

I suspect the usual explanation for this is wrong, or at least incomplete.

I am aware this may have a boring answer. I would still like the boring answer stated clearly.

What is actually going on here, physically?

Concretely, answering this requires distinguishing the maximum studied dose from the maximum useful dose. The trials established the former. The latter is a per-person question that the trials were not designed to answer.

Steady state, worked: with a half-life of about seven days and weekly administration, the accumulation ratio is roughly 1/(1 − 0.5) = 2, and you get to within about 97 per cent of steady state after five half-lives, so around thirty-five days — five weeks — after any dose change. A four-week step interval therefore has you escalating at roughly 94 per cent of the previous dose’s steady state, which is close enough to be sensible and not so close as to be conservative.

Weekly dosing accumulation, 7-day half-life

This is why a four-week step interval is approximately, but not exactly, steady state.

Extending the interval and reducing the dose are not equivalent manoeuvres. Reducing the dose lowers the whole concentration-time curve proportionally. Extending the interval lowers the average but deepens the trough, and for a compound whose effect on appetite tracks concentration, a deep trough is felt.

The STEP programme escalated semaglutide over sixteen weeks in four-week steps to 2.4 mg weekly, and the trial-product estimand versus treatment-policy estimand distinction accounts for most of the difference between the figures quoted from those papers.

Worth noting that inter-individual variability in exposure at a given dose is substantial, which is why the ladder exists rather than a single population dose.

Escalate on tolerability, hold when it costs you, and do not confuse a flattening curve with a failing drug.

On the detail: four weeks is not a magic number, it is approximately five half-lives, which is the interval over which a weekly compound reaches steady state after a dose change. Escalating faster means escalating onto a rising concentration.

The argument against splitting a weekly dose is arithmetic rather than ideological. Peak-to-trough ratio for a seven-day half-life compound dosed weekly is about two. Split it into twice-weekly and the ratio falls to roughly 1.4. That is a real reduction in fluctuation and a negligible one in absolute terms, and you have doubled the number of stopper piercings and the number of small-volume measurements, each of which carries its own error.

Put another way, holding at a step for longer than four weeks before escalating does appear to reduce cumulative gastrointestinal burden, which is unsurprising given that adverse events cluster in the one to two weeks after each increase. What it does not do is change where you end up, provided you get there.

The label instructions for a missed weekly dose differ between agents, and reading the actual prescribing information rather than a summary is worth the ten minutes — the thresholds are specific and the reasoning behind them is stated.

If you take one thing from this: dose rate drives tolerability, dose level drives exposure, and they are separate levers.